NIH is prioritizing Human-based Research Models - How Advanced Solutions’ Organoid360™ Can Help You Adapt
- Advanced Solutions
- 2 days ago
- 2 min read
A Historic NIH Decision That Changes the Research Landscape
On July 7, 2025, the National Institutes of Health (NIH) announced it will no longer issue new funding opportunities that focus exclusively on animal models. From now on, all new NIH grant announcements must include - or allow for - human-relevant research approaches, often referred to as New Approach Methodologies (NAMs).
This shift means researchers seeking NIH funding must incorporate methods like organoids, microphysiological systems, organ-on-a-chip, advanced in vitro models, and AI-driven simulations into their study designs.
For labs built on traditional animal-only workflows, this marks a major change.
For innovators already using human-relevant models - it’s an opportunity.
Why This Matters for Researchers
The NIH’s updated policy doesn’t eliminate animal research, but it does elevate hybrid approaches that improve translatability to human health.
In practice, this means:
Proposals that integrate NAMs alongside animal models will have a competitive advantage.
Reviewers will be looking for human-relevant data early in the research pipeline.
Researchers who adapt now will be better positioned for long-term funding success.
How Advanced Solutions Can Help You Compete
At Advanced Solutions Life Sciences, we’ve spent years building platforms that make it easier for scientists to incorporate NAMs into their research and create a profound and positive impact.
Our latest innovation, the Organoid360™ Bundle was designed with exactly this type of policy shift in mind.
With Organoid360™, you can break through NAMs roadblocks:
Labs can meet NIH expectations without disrupting existing workflows - instead, you enhance them with scalable, compliant NAM capabilities.
A Turnkey Path to NIH-Ready Research
Because Organoid360™ combines hardware, software, and workflow support, it’s not just a piece of equipment - it’s a full research ecosystem.
This means:
Faster adoption: No need to design your own organoid pipeline from scratch (but our platforms are friendly with pre-existing workflows!)
Improved reproducibility: Turn-key automation ensures consistent, reliable results.
Relevant workflows: The platform’s output is designed for human-relevant translational research, aligning perfectly with NIH’s stated priorities.
The Bottom Line
With Organoid360™, Advanced Solutions empowers researchers to address new funding dynamics and generate the kind of high-quality data that advances science - and wins grants.
Ready to make your research NIH-ready? Contact an ASLS specialist today to see how our solutions can integrate into your lab and position your next grant proposal for success.